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Abstract
Background: Tumors avoid destruction by cytotoxic T cells (CTL) and natural killer (NK) cells by downregulation
of classical human leukocyte antigens (HLA) and overexpression of non-classical HLA. This is the first study to
investigate HLA expression in relation to histology (squamous cell carcinoma (SCC) vs. adenocarcinoma (AC)),
clinicopathological parameters and survival in a large cervical cancer patient cohort.
Methods: Classical (HLA-A and HLA-B/C)- and non-classical HLA molecules (HLA-E and HLA-G) were studied on primary
tumors and paired lymph node (LN) metastases from cervical cancer patients (n = 136) by immunohistochemistry. The
Chi2 test was used for the comparison of clinicopathological characteristics between SCC and AC patients. The Related-
Samples Wilcoxon Signed Rank test was used to compare HLA expression between the primary tumor and metastasis in
LN. Patient survival rates were analyzed by Kaplan-Meier curves and Log Rank test. The Mann-Whitney U Test was used
to compare the distribution of HLA class I expression between SCC and AC.
Results: Decreased expression of HLA-A (SCC P < 0.001), HLA-B/C (SCC P < 0.01; AC P < 0.01) and total classical
HLA (SCC P < 0.001; AC P = 0.02) was apparent in metastatic tumor cells compared to the primary tumor. In
primary SCC, there was a clear trend towards complete loss of HLA-A (P = 0.05). SCC metastases showed more
complete loss of HLA-A, while AC metastases showed more complete loss of HLA-B/C (P = 0.04). In addition,
tumor size and parametrium involvement were also related to aberrant HLA class I expression. No significant
associations between HLA expression and disease-specific (DSS) or disease-free survival (DFS) were found in this
advanced disease cohort. However, in the SCC group, samples showing loss of HLA-A or loss of total classical
HLA but positive for HLA-G were linked to poor patient survival (DSS P = 0.001 and P = 0.01; DFS P = 0.003 and
P = 0.01, for HLA-A and total classical HLA, respectively).
Conclusion: These results strengthen the idea of tumor immune escape variants leading to metastasis. Moreover,
SCC tumors showing downregulation of HLA-A or total classical HLA in combination with HLA-G expression had
poor prognosis. Our findings warrant further analysis of HLA expression as a biomarker for patient selection for
CTL- and NK- cell based immunotherapeutic intervention.
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Background
A persistent human papilloma virus (HPV) infection and
concomitant expression of the HPV E6 and E7 oncogenes
are important mediators of the development of cervical
cancer [1]. Principally, HPV-antigens and tumor-derived
antigens should trigger activation of the immune system
and subsequent destruction of infected cells and/or bur-
geoning (pre-) malignant lesions. However, HPV-infected
and transformed cells can acquire a number of immune
escape mechanisms to avoid the host’s immune system,
resulting in eventual tumor growth and lymph node (LN)
metastasis [2–4].
One of the mechanisms by which tumor cells can es-
cape immune destruction, is downmodulaton of classical
human leukocyte antigens (HLA) class I (HLA-A, -B,
and -C) expression. These molecules are responsible for
tumor-associated antigen presentation at the cell surface
for recognition by cytotoxic T cells (CTLs) and targeted
cell lysis [2–6]. In addition, tumor cells are able to in-
crease the expression of non-classical HLA class I mole-
cules (HLA-E and HLA-G), which can interact with the
inhibitory receptors CD94/NKG2A and KIR2DL4/p49 on
natural killer (NK) cells, as well as on effector T cells and
myeloid cells (e.g., ILT2 and ILT4), leading to decreased
NK cell and/or T cell effector activity and hereby potential
tumor progression [7–11]. However, it has also been re-
ported that KIR2DL4 can act as a stimulatory molecule
[12]. In addition, HLA-E can also bind the stimulatory
CD94/NKG2C receptor of NK cells, this might have less
impact because of a 6-fold lower affinity as compared to
the inhibitory receptors [13].
In cervical cancer, we and others have described loss
of classical HLA class I [14–23], and expression of
HLA-E and HLA-G at the site of the primary tumor
[23–25]. In addition, some studies have compared HLA
class I expression between primary cervical carcinoma
and paired metastatic LNs [26–28]. In these studies,
the patient groups were small and no comparison was
made between the different histological subtypes, squa-
mous cell carcinoma (SCC) and adenocarcinoma (AC),
despite substantial differences between these two types
regarding clinical outcome, oncogenic mutations, and
immunological characteristics as shown by us and by
others [24, 29–36].
The HLA class I status of primary and metastasized cer-
vical tumor cells could be of clinical relevance to predict
the response to chemotherapy [37] and to immunotherapy
focusing on activating CTLs or NK cells in order to des-
troy tumor cells [38, 39]. In this study, we compared the
expression of classical and non-classical HLA molecules
between SCC and AC in primary tumors and synchronous
metastatic LNs in a large group of patients, and linked
these data with clinicopathological characteristics and
outcome.
Methods
Patients and ethical approval
From 136 patients with cervical cancer and LN metas-
tasis (SCC n = 103 and AC n = 33) diagnosed between
1986 and 2008, formalin-fixed, paraffin-embedded tis-
sue blocks with primary cervical cancer and paired
metastasis-positive LN were obtained from the archives
of the Departments of Pathology at the VU University
Medical Center (VUmc) Amsterdam (n = 42), Academic
Medical Center (AMC) Amsterdam (n = 86), and Leiden
University Medical Center (LUMC) (n = 8) in The
Netherlands. The main clinicopathological characteristics
of the patients were retrieved from the databases available
at the Pathology departments and Gynecology depart-
ments at the different institutes and are summarized in
Table 1. None of the patients underwent chemotherapy or
radiotherapy before surgery.
All human tissue samples in this study were coded an-
onymous, and were used according to the medical ethical
guidelines described in the Code Proper Secondary Use of
Human Tissue established by the Dutch Federation of
Medical Sciences (http://www.federa.org) [40].
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks were
sectioned at 4 μm and mounted on StarFrost slides
(Waldemar Knittel, Germany). Slides were deparaffi-
nized in 3× xylene and washed in 1× 100 %, 1× 90 % of
ethanol. Then, endogenous peroxidase was blocked
with 0.3 % H2O2 (MERCK, Germany) in methanol for
20 min. Slides were rehydrated in 1× 70 % of ethanol
and 1× demineralized water and heated in a microwave
for antigen retrieval for 10 min in boiling 0.01 M citrate
buffer pH 6.0 (for classical HLA-A, -B/C and HLA-E)
or Tris/EDTA buffer pH 9.0 (for HLA-G). The slides
were allowed to cool down for 1 h at room temperature
(RT). After antigen retrieval, all slides were washed
with 2× demineralized water and 2× phosphate buffered
saline (PBS) and incubated over night at RT with one of
the following antibodies diluted in 1 % BSA/PBS; mouse-
anti-HCA2 (HLA-A), mouse-anti-HC10 (HLA-B/C) (both
antibodies provided by Prof. Neefjes from the Dutch
Cancer Institute, NKI-AvL, Amsterdam), mouse-anti-
HLA-E (MEM-E/02; AbD Serotec, UK), and mouse-anti-
HLA-G (4H84; BD Pharmingen™, USA). The next day,
slides were washed 3× in PBS and incubated with Bright-
Vision (ImmunoLogic, The Netherlands) for 30 min at
RT. Then, slides were washed 3× in PBS, after which im-
mune complexes were visualized with 0.05 % solution of
3,3′-Diaminobenzidine (DAB) containing 0.0018 % H2O2
in a 0.05 M Tris–HCl buffer (pH 7.6) for 10 min in the
dark at RT. Finally, the sections were counterstained with
Haematoxylin followed by 5 min rinsing with running tap
water. Finally, slides were dehydrated and mounted under
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coverslips with Quick-D mounting medium (Klinipath,
The Netherlands).
Imaging and scoring
Sections were scored by the percentage and intensity of
the immunostained tumor cells using an Olympus BX50
bright-field microscope (Olympus, USA) by three investi-
gators (D.M.F., A.M.H., and E.S.J.). Stromal cells and infil-
trating immune cells served as an internal positive control
for HLA-A, -B/C and -G detection, while vascular cells
served as an internal positive control for HLA-E detection.
The percentage of classical HLA class I positive tumor
cells was scored as 0 for absent, 1 for sporadic (1–5 %), 2
for local (6–25 %), 3 for occasional (26–50 %), 4 for major-
ity (51–75 %), and, 5 for large majority (76–100 %).
Secondly, the intensity of the staining was scored as 0 (ab-
sent), 1 (dull), 2 (clear), or 3 (strong), based on compari-
son with the normal cells present in the same sample. The
sum of both scores (percentage and intensity) were used
to identify three categories for classical HLAs (0–2 as
complete loss of expression, 3–6 as weak expression, and
7–8 as normal expression) and two categories for non-
classical HLAs (0–4 as no expression and 5–8 as expres-
sion) as previously described by Ruiter et al. [41]. For non-
classical HLA score a cut off of 5 was used to define
groups [24]. Total classical HLA scoring was based on the
combined scores of HLA-A and -B/C [21].
Statistical analysis
All statistical analyses were performed using SPSS 20 stat-
istical software (SPSS 20.0, SPSS Inc. Chicago, IL, USA).
The Chi2 tests (Pearson Chi2 and Linear-by-Linear Associ-
ation, Asymptotic or Exact tests, two-sided) were used for
the comparison of clinicopathological characteristics be-
tween SCC and AC. The Related-Samples Wilcoxon
Signed Rank test was used to compare HLA expression
between the primary tumor and metastasis in LN. Patient
survival rates were analyzed by Kaplan-Meier curves and
the Log Rank (Mantel-Cox) test. The Mann-Whitney U
Test was used to compare the distribution of HLA class I
expression between SCC and AC. Differences were con-
sidered statistically significant when P < 0.05.
Results
Clinicopathological characteristics of SCC vs AC
Patients diagnosed with metastatic AC, manifested with
a higher recurrence rate (P = 0.014, Chi2 test) (Table 1).
Furthermore, these patients had a worse 5-year disease-
specific (DSS) and disease-free survival (DFS) compared
to patients with SCC (P = 0.003 and P = 0.006, respect-
ively, Log Rank test) (Fig. 1).
HLA class I expression in primary cervical cancer and
paired metastatic LN
HLA class I expression in paired primary tumor and LN
metastasis samples of SCC and AC was analyzed by im-
munohistochemistry for HLA-A, HLA-B/C, HLA-E and
HLA-G. Representative examples of classical and non-
classical HLA expression are depicted in Fig. 2. The results
obtained for HLA class I expression are summarized in
Additional file 1: Table S1 and shown in Fig. 3.
Table 1 Clinicopathological characteristics of the study cohort
Clinicopathological characteristics SCC AC P - value






IBI 60 (58.2) 20 (60.6)
> = IBII 42 (40.8) 13 (39.4)
Missing 1 (1) 0 (0.0)
Tumor size 0.448
< =4 cm 72 (69.9) 25 (75.8)
> 4 cm 29 (28.2) 7 (21.2)
Missing 2 (1.9) 1 (3.0)
Vaginal involvement 0.191*
Yes 17 (16.5) 1 (3.0)
No 84 (81.6) 22 (66.7)
Missing 2 (1.9) 10 (30.3)
Parametrium invasion 0.122
Yes 38 (36.9) 7 (21.2)
No 63 (61.2) 24 (72.7)
Missing 2 (1.9) 2 (6.1)
Progression 0.303
Yes 32 (31.1) 13 (39.4)
No 65 (63.1) 14 (42.4)
Missing 6 (5.8) 6 (18.2)
Recurrence in 5 years 0.014
Yes 30 (29.1) 18 (54.5)
No 64 (62.1) 14 (42.4)
Missing 9 (8.7) 1 (3.0)
Progression: determined by physical examination, pathological or
radiological assessment
Recurrence: recurrence after a complete remission due to the treatment
P-value measured with Asymptotic Pearson Chi2; (*)Exact test was used when
counts were less than 5; (#)Mann-Whitney U Test was used for
mean comparison
Data shown as n (%)
FIGO International Federation of Gynecology and Obstetrics, SCC squamous
cell carcinoma, AC adenocarcinoma
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Classical and non-classical HLA class I expression in SCC
Most primary SCC tumors manifested with downregula-
tion (including cases both with complete loss and weak
expression) of HLA-A (79 %), HLA-B/C (90 %), and
total classical HLA expression (94 %). Metastatic tumor
cells in the LN, showed also downregulation of HLA-A
(92 %), HLA-B/C (96 %), and total classical HLA (98 %).
Unsurprisingly, there was a clear association between
loss of HLA in the primary tumor and the metastatic
LN (Additional file 1: Table S1). However, more import-
antly, we found a significantly lower expression of clas-
sical HLA class I in SCC paired metastatic tumor cells
for HLA-A (P < 0.001, Wilcoxon Signed Rank test),
HLA-B/C (P = 0.005, Wilcoxon Signed Rank test), and
total classical HLA (P < 0.001, Wilcoxon Signed Rank
test).
In addition, HLA-E expression was detected in 37 %
and HLA-G- in 22 % of the primary tumors (Additional
file 1: Table S1). There was significantly less HLA-E ex-
pression in the metastatic LN than in the paired primary
tumor (P = 0.035, Wilcoxon Signed Rank test). No other
significant correlations were found.
Classical and non-classical HLA class I expression in AC
In AC, most tumors manifested with downregulation
(including cases both with complete loss and weak ex-
pression) of HLA-A (77 %), HLA-B/C (77 %), and total
classical HLA (84 %). At the metastatic LN, tumor cells
also showed downregulation of HLA-A (80 %), HLA-B/
C (87 %), and total classical HLA (87 %). As was the case
for SCC, in AC there was a clear association between
loss of HLA in the primary tumor and the metastatic
LN (Additional file 1: Table S1). In the paired metastatic
AC samples a significantly lower expression of HLA-B/C
(P = 0.007, Wilcoxon Signed Rank test) and total clas-
sical HLA (P = 0.021, Wilcoxon Signed Rank test) was
found compared to the primary tumor.
At the site of the primary tumor, we observed 33 and
31 % expression of HLA-E and HLA-G, respectively.
The metastatic tumor cells showed less expression of
HLA-E (26 %) and HLA-G (28 %), however, this was not
significant.
Comparison of HLA class I expression between SCC and AC
When complete loss and weak expression of HLA-A
were compared between the histological subtypes, we
found a trend toward more complete loss in primary
SCC (P = 0.053, Chi2 test - pairwise) and SCC metastatic
LN (P = 0.081, Chi2 test - pairwise) (Fig. 4a). In the
metastatic LN, HLA-A and HLA-B/C expression pat-
terns were significantly different between SCC and AC
(for both P = 0.045, Chi2 test); in SCC, there were more
LNs with complete loss of HLA-A expression (Fig. 4a),
while in AC there were more LNs with complete loss of
HLA-B/C (Fig. 4b). No significant differences for the
remaining HLA molecules were found between SCC and
AC for the primary tumor or the LN.
Association of HLA class I expression and
clinicopathological parameters
In SCC, larger tumors (= > 40 mm) showed more often
complete loss as compared to partial loss of HLA-A (40 %
vs. 17 %) and total classical HLA (45 % vs. 21 %) expres-
sion (P = 0.034 and P = 0.027, Chi2 test – pairwise). In
addition, parametrium involvement was associated with
complete as compared to partial loss of HLA-B/C (54 %
vs. 31 %) and total classical HLA (54 % vs. 33 %) in the
metastatic tumor cells (P = 0.037 and P = 0.050, Chi2 test
Fig. 1 Survival analysis stratified for SCC and AC subtypes. 5-year Kaplan Meier survival curves and Log Rank test show a significantly poorer dis-
ease specific survival (DSS) (a) and disease free survival (DFS) (b) for patients with metastatic AC compared to patients with metastatic SCC. For
SCC, DSS data was missing for 12 and DFS data- for 15 cases. For AC, DSS data was missing for 3 cases and DFS data for 2 cases
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– pairwise). Surprisingly, expression of HLA-G (in 83 % of
the cases) in the metastatic tumor cells was also signifi-
cantly more often present in cases without parametrium
involvement (P = 0.034, Chi2 test).
In AC, larger tumors (= > 40 mm) showed more often
complete loss (67 %) compared to partial loss (14 %) of
HLA-A expression (P = 0.037, Chi2 test - pairwise). No
other significant associations were found.
Survival and HLA class I expression
Log rank test was performed and Kaplan-Meier plots
were generated for DSS and DFS to assess the correl-
ation with classical and non-classical HLA expression in
the primary tumor and metastatic LN. We found no
significant associations between classical HLA class I
expression and DSS (Additional file 2: Figure S1) nor
DFS (not shown) for both histological types. Noticeably,
patients with cervical AC with weak HLA-A expression
in the primary tumor cells had the poorest DSS (not
significant). Furthermore, AC patients with HLA-E ex-
pression in the primary tumor also appeared to have a
poor DSS (not significant).
In addition, we analyzed combinations of classical
and non-classical HLA expression patterns. In primary
SCC two significant findings were made; patients with-
out HLA-A expression but with HLA-G expression had
the worst DSS (P = 0.001) and DFS (P = 0.003) (Fig. 5).
The same was true for the patients with complete total
Fig. 2 Representative examples of HLA expression patterns in the primary tumor and corresponding metastatic tumor sample. a Heterogeneous
HLA-A expression in SCC on the cell membrane of the primary tumor cells (T). In the corresponding LN, no HLA-A was expressed by the metastatic
tumor cells (T in lower panel), while it is expressed by surrounding immune cells. b Primary tumor cells (T) show membrane expression of HLA-
A (indicated by black arrow, upper panel). Metastatic tumor cells (T in lower panel) in corresponding LN show less expression of HLA-A
compared to the primary tumor. c Primary AC shows a high cytoplasmic expression of HLA-A (T in upper panel). In the corresponding LN
metastasis, there is loss of HLA-A expression in the tumor cells (T in lower panel), while it is expressed by surrounding immune cells. d Low
expression levels of HLA-G in primary SCC (T in upper panel) and in the corresponding metastatic tumor cells (T in lower panel). e Primary AC
(T in upper panel) show low expression levels of HLA-G, while in the corresponding metastatic tumor cells (T in lower panel), HLA-G is abundantly
expressed at the cell surface. f Primary AC (T in upper panel) show high expression levels of HLA-G, while HLA-G is not expressed in the corresponding
metastatic tumor cells (T in lower panel). Scale bar is 50 μm
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classical HLA loss but with HLA-G expression (DSS
P = 0.014, DFS P = 0.010) (Fig. 5).
Concerning DSS and DFS of AC patients, no signifi-
cant correlations were observed and no conclusions
could be drawn as the number of AC patients per group
was too limited.
Discussion
We believe the present study to be the first to include a
large cervical cancer patient cohort and to report on the
differences between SCC and AC, regarding classical
and non-classical HLA expression in paired primary tu-
mors and metastatic LN and to relate the expression
patterns to clinicopathological characteristics and patient
survival. In the past, only one publication on a small cer-
vical cancer cohort (n = 26) has reported analysis on pri-
mary tumor and paired metastatic LN and has taken the
two major histological subtypes into account [42].
Here, the vast majority of SCC and AC manifested with
downregulation of classical HLA at the site of the primary
tumor and even lower expression in the metastatic tumor
cells. This phenomenon has been also observed in other
tumor types, like breast-, lung-, and liver carcinomas [43,
44]. This is likely resulting in a decreased sensitivity to T
cell lysis, which is supported by the observed significant
correlation between HLA class I downregulation and a
decrease in tumor-infiltrating CD8+ T cells [27, 45], with
particularly lower numbers of CD8+ T cells in primary
tumors with weak HLA-A expression [21]. Moreover, this
outcome fits with the concept that tumor cells are posi-
tively selected based on low- or no expression of classical
HLA, caused by genetic alterations like HLA class I allele-
specific mutations, β2-microglobulin gene mutations, and
antigen processing machinery-associated mutations [19,
22, 46, 47], and can be linked to invasiveness and meta-
static potential [16, 48–50]. Previously, Menon et al. re-
ported on the lack of downregulation of HLA class I in
liver metastasis compared to primary colorectal cancer
samples [51], however, we and others showed the oppos-
ite, probably explained by differences in the microenviron-
ment of the metastatic site; liver metastasis versus lymph
node metastasis. Interestingly, we did find a trend towards
more HLA-A complete loss in primary SCC tumors com-
pared to primary AC tumors, which was also observed in
Fig. 3 HLA expression distribution in primary tumor samples compared to metastatic tumor samples. Classical (a) and non-classical (b) HLA class I
expression of primary tumor samples compared to metastatic tumor samples of patients with SCC. Classical (c) and non-classical (d) HLA class I
expression of primary tumor samples compared to metastatic tumor samples of patients with AC. In A and C: ‘+’ is normal expression, ‘+/-‘is weak
expression, and ‘-‘is complete loss. In B and D: ‘-‘is no expression and ‘+’ is normal expression
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the LNs and supported by another study in cervical cancer
patients [42]. In addition, complete loss of HLA-A was as-
sociated with larger tumors in both SCC and AC, which is
consistent with a study in breast cancer reporting that lar-
ger tumors manifest with low HLA class I expression [44].
The crucial role of the non-classical HLA molecules
was recently demonstrated in large cohorts of breast
[52], ovarian [53] and colorectal [54] cancer patients.
Until now only HLA-E was studied in SCC and AC pri-
mary cervical cancer samples and high expression of
HLA-E was found in 56 %, with significantly higher ex-
pression in cervical AC compared to SCC [24]. In con-
trast, in the present study, we found 30 % expression of
HLA-E in the primary tumor for both groups. This dif-
ference might be explained by the fact that we analyzed
an advanced-stage, metastatic patient group, while HLA-E
expression might be an earlier event in tumor progression
[44]. In fact, in SCC, there was significantly less HLA-E
expression in the metastatic tumor cells compared to the
primary tumor.
In previous studies, HLA-G expression was found in
27–30 % of the primary- [28, 55] and 11 % of the meta-
static tumor samples [28], but without histological sub-
typing. Here, comparable results were obtained with
approximately 25 % of the cases having expression of
HLA-G in the primary tumor and 11 % in the metastatic
LNs. No significant differences were observed between
histological subtypes.
Next to the association between primary tumor, me-
tastases and clinical parameters, we analyzed the import-
ance of classical HLA loss and non-classical HLA
expression for patient survival. As here we have focused
on an advanced, metastatic patient cohort these patients
already had a worse prognosis than patients without me-
tastases [56, 57]. We could identify significantly higher
progression rates and a significantly poorer outcome for
patients with metastatic AC compared to patients with
metastatic SCC, which is in accordance with earlier
studies showing AC to be the more aggressive subtype
[58, 59]. Studies on penile cancer [60], colorectal cancer
Fig. 4 Comparison of HLA expression patterns in primary tumor and metastatic tumor samples. The distribution of (a) HLA-A and (b) HLA-B/C
expression in LN is significantly different between patients with SCC and AC (for both P = 0.045, Chi2 test). In SCC, more complete loss of HLA-A
expression was observed in primary tumor and LN, while in AC, there was more weak expression of HLA-A in primary (P = 0.053, pairwise Chi2
test) tumor and LN (P = 0.081, pairwise Chi2 test). NB: We cannot exclude the possibility of HLA haplotype loss or HLA allelic loss as previously
described [19] in the cases defined as having ‘normal HLA expression’ since these were solely based on HCA2 and HC10 staining
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[61], and primary cervical cancer (including a mixed
SCC and AC patient cohort with or without metastasis)
[21], described a strong association between partial loss
of HLA expression and poor prognosis. In contrast, we
did not find significant associations between classical
HLA expression and survival rates. Possibly, due to the
obvious poor survival of this metastatic patient group,
contrary to previous findings, we could not confirm sur-
vival advantage for AC patients with HLA-E expression
in the primary tumor [24].
Although very low numbers of NK cells are present in
cervical tumors [21, 62], downregulation of classical
HLA may lead to decreased sensitivity of T cell lysis, but
simultaneously may enhance sensitivity to NK cell lysis
[48], we studied classical HLA expression in combin-
ation with non-classical HLA expression. Interestingly,
SCC patients with HLA-G expression in combination
with downregulation of HLA-A or total classical HLA in
the primary tumor had a significantly poorer DSS and
DFS, which is in accordance with a study in breast can-
cer [52]. Previous studies, including cervical cancer, also
reported on HLA-G upregulation in case of classical
HLA loss [44, 55, 63]. However, our findings should be
interpreted with caution, because of the limited number
of patients per group and the limited number of patients
with normal expression of classical HLA in the present
patient group (eight for SCC and five for AC). The same
holds true for the metastases group; there were only two
SCC metastases and four AC metastases with normal
HLA class I expression.
Conclusion
In conclusion, in both histological tumor types, SCC and
AC, our results show evidence of aberrant patterns of
HLA expression with even lower classical HLA class I
expression in corresponding LN metastases. Our study
is likely to be an under-representation of the actual HLA
aberrations due to specific allele mutations, which can-
not be identified by immunohistochemistry. In patients
with primary SCC, complete loss of classical HLA was
found more frequently than in patients with AC (P =
0.05), suggesting that this is one of the important mech-
anisms for tumor progression in SCC. Based on these
findings, we speculate that there could be a more pro-
nounced immunological pressure on SCC cells to com-
pletely downregulate classical HLA expression thereby
becoming less sensitive for T cell lysis. Moreover, this
immunological pressure is prominent in SCC tumors, in
which downregulation of HLA-A or total classical HLA
in combination with HLA-G expression is related to
poor prognosis, suggesting escape from both T cell and
NK cell antitumor activity.
It would be of great interest to study the differences in
quality and quantity of HPV-specific immune responses
between SCC and AC, since AC is more frequently asso-
ciated with HPV18 [64]. Recently, Safaeian et al. found
Fig. 5 Survival plots for SCC patients, combining classical HLA and HLA-G expression in the primary tumor. 5 year disease-specific survival (DSS)
(a) and disease-free survival (DFS) (b) curves for SCC patients in relation to HLA-A/HLA-G expression and total classical HLA/HLA-G expression in
the primary tumor. Both patient groups with down-regulated HLA-A(-) or total classical HLA(-) in combination with HLA-G expression had the
poorest survival (red line). Log Rank test P-value combining all groups, * Log Rank test P-value between classical HLA(-)/HLA-G(+) (red line) and
classical HLA(-)/HLA-G(-) (yellow line)
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an association between HLA allelic sub-types and HPV
type-specific peptides, suggesting that HLA recognition
is HPV type-specific [65]. In addition, reduced levels of
TNFα and IFNγ were found in HPV18-infected patients
compared to HPV16-infected patients [66], and less IL-6
and IL-12 was present in the supernatant of the SiHa
(HPV16+) cell line compared to the supernatant of the
HeLa (HPV18+) cell line, while both cell lines were able
to induce immunosuppressive M2 type marker CD163
expression on macrophages [67]. However, still not
much is known about the immunological differences
between SCC and AC. It is puzzling that AC retain
higher HLA class I expression levels as compared to
SCC. We have recently published on substantial differ-
ences between the SCC and AC histological subtypes
regarding oncogenic mutations, with e.g., KRAS muta-
tion exclusively found in AC [31]. In contrast, we found
EGFR upregulation exclusively in SCC [68]. Currently,
we are focusing on understanding the immunological
differences between SCC and AC, and we are investi-
gating the presence of different immune cell subsets
which may give us more information on the different
role of HLA expression in these histological subtypes
[32–36]. In addition, there was more complete HLA-A
loss in SCC metastasis, while there was more complete
loss of HLA-B/C in AC metastasis, again emphasizing
the need for better immune-characterization of the two
major cervical cancer histological subtypes.
The translational relevance of these findings is poten-
tially high with the exponential rise of T cell based immu-
notherapeutic approaches in the past few years [69, 70] as
it is conceivable that tumor cells with low or absent clas-
sical HLA will not respond, or will respond differently, to
these therapies due to reversible or irreversible HLA class
I alterations [49, 71]. It will be of great interest to dissect
the effect of classical and non-classical HLA expression in
(metastatic) cervical cancer on the clinical effect of thera-
peutic vaccination and other immunotherapies, which will
potentially lead to the selection of a patient group that is
most likely to respond to this type of intervention.
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